High Court Justices Question Shareholders' "Loss" In Case Against Dura/Elan
This article was originally published in The Pink Sheet Daily
Executive Summary
In Dura v. Broudo oral arguments, several justices cite difficulty in connecting a February 1998 decline in the company's stock price, for which the shareholders seek compensation, with a disclosure nine months later that FDA deemed the company's Spiros albuterol device "not approvable."